A Phase II Trial of Multisite Stereotactic Radiation Therapy (SRT) or Stereotactic Body Radiation Therapy (SBRT) with PD-1 Inhibitor and GM-CSF for the Treatment of Chemo-Refractory Metastatic Solid Tumors